



Patent Application
Attorney Docket No. PC27819

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 6th day of April 2004.

By

(Signature of person mailing)

A. David Joran

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Bruce N. Rogers et al. :

APPLICATION NO.: 10/729,529 : Examiner:

FILING DATE: December 5, 2003 : Group Art Unit:

TITLE: COMPOUNDS AS RADIOLIGANDS :
FOR THE DIAGNOSIS OF DISEASE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.



Patent Application
Attorney Docket No.PC27819


A prompt and favorable response is earnestly solicited.

Date: April 6, 2004

Respectfully submitted,

A. David Joran
Attorney for Applicant(s)
Reg. No. 37,858

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)733 -3381



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC27819		SERIAL NO. 10/729,529			
									APPLICANT Bruce N. Rogers et al.					
									FILING DATE December 5, 2003		GROUP			
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US	5	9	6	9	1	4	4	10/19/99	London				
	US	0	0	4	9	2	2	5	4/25/02	Myers				
	US	0	0	9	0	1	3	5	7/11/02	Myers				
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	0	0	3	2	6	0	0	6/8/00	PCT				
	WO	0	2	1	6	3	5	5	2/28/02	PCT				
	WO	0	2	8	5	9	0	1	10/31/02	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		W. A. Hewlett et. Al., "Synthesis and 5-HT ₃ Receptor Binding of 2- and 3-(Halo)Alkoxy Substituted (S)-N-(1-Azabicyclo '2.2.2(oct-3-yl)-5-chlorobenzamides as Potential Radioligands", Nuclear Medicine and Biology, vol. 25, 1998, pages 141-53, XP004100819, figures 2, 5.												
		V.K. Sood et al., "In Vivo Autoradiography of Radioiodinated @-3-Quinucidinyl-(S)-4-Iodobenzilate (R,S)-IQNB and (R)-3-Quinucidinyl-@-4-Iodobenzilate (R,R)-IQNB", Applied Radiation and Isotopes, vol. 48, no. 1, 1997, pages 27-35, XP004117531, pages 28-9, Experimental Section.												
		A. G. Hori et. Al., "Radiosynthesis and Preliminary Evaluation of 5-'123'125I-Iodo-3-(2-(S)-Azetidylmethoxy)-pyridine. A Radioligand for Nicotinic Acetylcholine Receptors", Nuclear Medicine and Biology, vol. 26, 1999, pages 175082, XP004157107, figures 1-7.												
EXAMINER														
DATE CONSIDERED														
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														